Skip to main content

Mivocabtagene Autoleucel CD19 Chimeric Antigen Receptor T-Cell Therapy in Stiff Person Syndrome: A Nonrandomized Clinical Trial

In brief

CAR T therapy improves walking time by 46% in a small stiff person trial

In this single-arm study, 26 adults with stiff person syndrome improved their timed 25-foot walk by a median 46% at 16 weeks after one mivocabtagene autoleucel infusion; all remained off SPS immunotherapy at last follow-up. Most had mild cytokine release syndrome, and follow-up was short, so controlled studies and longer tracking are needed to establish how durable the benefit is.

Journal
JAMA neurology (Q1)
Published
9 November 2026
Study design
Phase 2 randomized trial (exploratory)
Evidence level
Level 2, Moderate (CEBM 2b)
Authors
Amanda L Piquet, Anastasia Zekeridou, Usama Gergis, Jonathan Gutman, Saad S Kenderian, Mallory Lowe, et al.
PMID
43002394
DOI
10.1001/jamaneurol.2026.4155

Why clinicians should know about it

  • Picked for Immunology and Allergy (paper of the day, 11 November 2026): Clinical CAR T-cell therapy trial for autoimmune stiff person syndrome

Abstract

IMPORTANCE: Stiff person syndrome (SPS) is a progressive, autoimmune neurologic disease characterized by muscle stiffness and painful spasms, leading to substantial disability. Mivocabtagene autoleucel, a fully human, autologous CD19 chimeric antigen receptor (CAR) T-cell therapy with CD28 costimulation, showed durable clinical benefit on a named-patient basis in SPS. OBJECTIVE: To evaluate the efficacy and safety of mivocabtagene autoleucel in adult SPS. DESIGN, SETTING, AND PARTICIPANTS: This pivotal, single-arm, open-label, nonrandomized phase 2 study enrolled participants from September 2024 to May 2025 at 3 US sites. Individuals aged 18 to 75 years with antibody-positive SPS and inadequate response to immunomodulatory/immunosuppressive therapies as determined by investigators were included. INTERVENTION: Patients received low-dose lymphodepletion (fludarabine, 30 mg/m2/d, and cyclophosphamide, 300 mg/m2/d, for 3 days), followed by a single mivocabtagene autoleucel infusion (1 × 108 CAR T cells). MAIN OUTCOMES AND MEASURES: Primary end points were the change from baseline to week 16 in the timed 25-ft walk (T25FW) and safety. Secondary end points were modified Rankin Scale score, Distribution of Stiffness Index score, Heightened Sensitivity Scale score, and Hauser Ambulation Index score. Exploratory end points included pharmacokinetic and pharmacodynamic assessments and biomarkers. RESULTS: Of 27 patients enrolled, 26 (median [range] age, 56.0 [32.0-73.0] years; 16 [61.5%] female) were treated. Median (range) follow-up was 6.5 (4.4-12.2) months. The primary efficacy end point was met, with significant week 16 improvement from baseline in T25FW of a mean of -7.69 seconds (SD, 10.03; 95% CI, -11.74 to -3.64; P < .001) and a median (IQR) of -4.8 (-11.9 to -2.5) seconds (45.6% median improvement); improvement was sustained (median, 44.4%) among 16 of 26 patients who reached the 24-week time point. All secondary efficacy end points showed significant week 16 improvements from baseline (modified Rankin Scale score: mean, -0.8 points [SD, 0.86; 95% CI, -1.1 to -0.4; P < .001], Distribution of Stiffness Index score: mean, -1.5 points [SD, 1.75; 95% CI, -2.2 to -0.8; P < .001]; Heightened Sensitivity Scale score: mean, -3.2 points [SD, 2.01; 95% CI, -4.0 to -2.3; P < .001]; Hauser Ambulation Index score: mean, -1.6 points [SD, 1.13; 95% CI, -2.1 to -1.2; P < .001]). The most common grade 3/4 treatment-related adverse event was neutropenia (5/26 patients [19.2%]). Low-grade cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome occurred in 24 of 26 patients (92.3%; 10/26 [38.5%] grade 1; 14/26 [53.8%] grade 2) and 3 of 26 patients (11.5%; all grade 1), respectively; all resolved without sequelae. B-cell depletion and clear changes suggestive of immune reset were observed. At last follow-up, all patients remained free of immunomodulatory therapies for SPS. CONCLUSIONS AND RELEVANCE: In this nonrandomized clinical trial, a single dose of mivocabtagene autoleucel resulted in immunotherapy-free remissions with a consistent, well-tolerated safety profile, demonstrating a highly effective therapy in antibody-positive SPS with the potential for durable remissions. Long-term follow-up is ongoing. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06588491.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.